by Jordana Choucair | Jan 10, 2023 | Life Sciences
Moderna Inc. said it may price its COVID-19 vaccine between $110 and $130 per dose in the United States when commercial distribution begins. The price is similar to the price Pfizer Inc. is considering for its shot developed with BioNTech SE. While the price range is...
by Jordana Choucair | Jan 10, 2023 | M&A
CVS Health Corp. is in talks to buy primary care operator Oak Street Health Inc. for more than $10 billion, including debt. Sources say that deal could be reached in the coming weeks, though they noted that the discussions could end without a deal. (Articles here and...
by Jordana Choucair | Jan 10, 2023 | Public Health/Prevention
The Biden administration may let the U.S. COVID-19 Public Health Emergency (PHE) declaration expire as early as the Spring. Under the current tentative plan, health officials will quietly renew the emergency declaration for another 90 days before its scheduled...
by Jordana Choucair | Jan 9, 2023 | Life Sciences
The Food and Drug Administration on Friday approved Leqembi – a new Alzheimer’s disease treatment that moderately slows cognitive decline in people with early-stage disease. Eisai Co., the Japanese pharmaceutical company that developed the drug with Biogen Inc., said...
by Jordana Choucair | Jan 9, 2023 | Life Sciences
Moderna Inc. said it pulled in $18.4 billion in COVID-19 vaccine sales last year, hitting its 2022 revenue forecast for the products. The company forecasted a minimum of $5 billion of sales this year. (Article here)
Recent Comments